Primary large cell neuroendocrine carcinoma of the prostate in a hormone naive patient: A case report from Taiwan

Research output: Contribution to journalArticle

2 Citations (Scopus)


Large cell neuroendocrine carcinoma (LCNEC) of the prostate is extremely rare. Previously reported cases in the literature were almost exclusively developed in men receiving androgen deprivation therapy for prostate adenocarcinoma. We herein present a case of de novo LCNEC: A 66-year-old male was incidentally diagnosed as LCNEC after he underwent transurethral resection of prostate. The stage was T4N1M1. Therefore, the patient was treated with 6 cycles of cisplatin and etoposide in the following 6 months, which achieved a partial remission. He gave up the chance to eradicate the residual mass. Three months later, the tumor progressed rapidly. In conclusion, LCNEC is a rare prostate cancer. Our experience shows that chemotherapy with etoposide and cisplatin is effective to achieve a significant remission. However, LCNEC is highly malignant in nature, postchemotherapy surgery for the residual mass should be considered.

Original languageEnglish
Pages (from-to)S785-S788
JournalJournal of Cancer Research and Therapeutics
Issue number10
Publication statusPublished - Jan 1 2018



  • Large cell
  • neuroendocrine tumor
  • transurethral resection of the prostate

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this